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Steroid hormones are widely known to influence expression of the hormone-responsive genes in target cells. 
The action of steroid hormones is known to be mediated by their initial binding to specific ‘receptor’ prote- 
ins. The exact sequence of events, which follow hormone binding and lead to a cellular response, has re- 
mained unclear. This timely meeting has provided a forum for discussion of the recent advances in the field, 
which explore the structure and function of steroid receptors in health and disease. 
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1. INTRODUCTION 
During the last two decades, progress in steroid 
hormone research has resulted in the development 
of new approaches to contraception as well as 
diagnosis and treatment of endocrine disorders 
and cancers. Although significant advances have 
been made in the purification, characterization, 
immunochemistry and molecular biology of 
steroid receptors, the precise molecular mechanism 
of steroid hormone action has remained obscure. 
The purpose of this international conference was 
to facilitate scientific exchange toward a better 
understanding of the mode of action of steroid 
hormones. The scientific sessions consisted of both 
poster presentations and state-of-the-art lectures, a 
brief summary of the latter is presented in this 
report. 
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The conference opened with a keynote address 
by Jack Gorski (Madison) who provided a historic 
perspective of the field of steroid receptors, citing 
earlier works of Szego and Roberts (1953) and 
Gerald Mueller (1958) that depicted possible sites 
of hormonal regulation of induced proteins. 
Laboratories of Jensen and Gorski and others 
subsequently demonstrated the presence of specific 
receptor proteins for estrogen. These studies in the 
late 60’s led to the ‘translocation’ or ‘two-step’ 
model of steroid hormone action. During the past 
few years the contention that unoccupied receptors 
are located in the cytoplasm has undergone 
modification and the nuclear localization of both 
ligand-free and liganded receptors has been de- 
fined in various systems. 
2. MOLECULAR ORGANIZATION, 
RECEPTOR STRUCTURE AND 
MODIFICATION 
Jean-Marie Gasc (Paris) presented evidence that 
under a variety of experimental conditions, an- 
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tibodies to chick progesterone receptor (PR) reveal 
the presence of receptor molecules in the cell nuclei 
independent of receptor occupancy by ligands. It 
was proposed that the occurrence of PR in the 
cytosol could be due to a loss or leak of nuclear 
receptor during homogenization. In contrast, 
glucocorticoid receptor (GR) was revealed by im- 
munostaining in both the cytoplasmic and the 
nuclear compartments. Furthermore, ligand ad- 
ministration led to intensification of immunostain- 
ing in the nucleus, as was also reported by 
Carlstedt-Duke and Brenner. Although these latter 
observations lend support to the nuclear transloca- 
tion hypothesis, intensified nuclear staining of GR 
following hormone administration could also sug- 
gest that steroid binding allows a better and pro- 
longed nuclear retention during experimental 
processing. 
Results presented by Robert Brenner (Beaver- 
ton) on the immunocytochemical studies in the 
reproductive systems of control and spayed 
nonhuman primates also supported the concept of 
nuclear localization of estrogen receptor (ER) and 
PR. Spayed monkeys exhibited nuclear staining 
for ER, although the receptor was measurable in 
the cytoplasm by cell-free binding assays. Brenner 
suggested that different cell types in the target 
organs of the reproductive tract regulate their ER 
and PR levels differently, and that stromal cells 
may interact with epithelial cells by paracrine 
mechanisms during steroid hormone action. 
In order to probe the molecular properties of the 
surface of ER, Hansen and Gorski (Madison) 
studied the partitioning behavior of ER in aqueous 
two-phase polymer systems and noted that both 
hormone binding and elevated temperature alter 
surface properties of ER. Partitioning of ER in 
biphasic polymer systems, according to Hansen, 
has revealed the existence of two independent con- 
formational transitions that occur within the 
receptor monomer. Alteration that occurs upon 
hormone binding modulates the hydrophobic con- 
tent of the receptor while the temperature- 
dependent ER transition is a hormone-independent 
irreversible structural change that apparently 
begins to occur upon homogenization and extrac- 
tion of receptor into cytosol. 
Steroid binding ability of uterine ER may be 
reversibly altered upon phosphorylation on 
tyrosine. Ferdinand0 Auricchio (Naples) discussed 
214 
identification of (i) a CaL+-stimulated kinase that 
phosphorylates ER on tyrosine and confers on it a 
hormone-binding ability and (ii) a phosphotyro- 
sine phosphatase whose action causes loss of hor- 
mone binding. Furthermore, phosphorylation on 
tyrosine is not a phenomenon unique to ER. Anti- 
phosphotyrosine antibodies were shown to re- 
cognize both ER and rat liver GR. 
Employing immunochemical analysis, David 
Toft (Rochester, MN) reported the existence of 
avian PR as two forms, A (79 kDa) and B 
(110 kDa), both of which exist as phosphoproteins 
and whose origin and significance remain unclear. 
Excessive homogenization, storage of tissue and 
exposure to elevated temperature are conditions 
detrimental to the receptor’s ability to bind steroid 
in target tissue cytosols. Within a 5-min period of 
progesterone administration, a time-dependent in- 
crease in receptor phosphorylation was evident, 
implying that receptor phosphorylation occurs 
very early in progesterone action. 
The native mammalian PR for human breast 
cancer cells, as presented by Kathryn Horwitz 
(Denver), consists of two independently synthe- 
sized 8 S receptors, one of which contains B- 
protein (120 kDa) and the other A-protein 
(94 kDa). Both receptor forms A and B bind to 
DNA and can produce biologic effects. Treatment 
with progesterone of T47Dc, cells, an estrogen- 
resistant human breast tumor cell line in which PR 
is constitutively expressed, leads to down- 
regulation of immunoreactive A and B receptors 
followed by their replenishment. 
The relationship of structural and functional do- 
mains of rat liver GR was discussed by Carlsted- 
Duke (Huddinge), who reported purification of 
receptor (94 kDa) in its monomeric DNA binding 
form. Limited proteolysis revealed that GR con- 
sists of three functional domains, namely, C- 
terminal steroid binding domain, a central DNA- 
binding domain and an N-terminal domain of 
uncertain function. Three amino acids, Met-622, 
Cys-754 and Cys-654 appear to interact with the 
steroid in the hormone-binding domain of GR. 
3. PHARMACOLOGY AND CLINICAL 
CONSIDERATIONS 
Detection and quantitation of both ER and PR 
are now used routinely in the clinical management 
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of breast and endometrial cancers as predictive in- 
dices of a patient’s response to endocrine therapy, 
and as prognostic indicators of a patient’s clinical 
course. James Wittliff (Louisville) discussed the 
origin and physiological significance of receptor 
heterogeneity observed with breast cancer patients. 
It was suggested that post-transcriptional 
modifications, such as receptor phosphorylation 
and association of steroid-binding peptide with 
nonhormone-binding peptides or protein kinases 
may contribute to polymorphism. Erlio Gurpide 
(New York) suggested that the presence of recep- 
tors in breast cancer or endometrial adenocar- 
cinema reveals cellular properties that make the 
tumor more responsive, without implying 
receptor-mediated effects of drugs with hormonal 
action. It was shown that receptor levels correlate 
with DNA polymerase and ornithine decarbox- 
ylase activities in certain endometrial cancer cell 
lines and that in estrogen-nonresponsive tumor 
cells, the ability of ER to interact with a 
monoclonal anti-ER antibody is impaired. 
Henry Rochefort (Montpellier) described how in 
ER-positive human breast cancer cell line, MCF-7, 
estrogens pecifically increase the secretion into the 
culture medium of a 52 kDa glycoprotein and 
stimulate cell proliferation. The 52 kDa protein 
has been identified as a secreted precursor of a 
cathepsin D, and is mitogenic in vitro in estrogen- 
deprived MCF-7 cells. The concentration of total 
cellular cathepsin D is related to the proliferation 
of mammary ducts and to the prognosis of breast 
cancer. The 52 kDa protease, according to 
Rochefort, appears to be useful as a tissue marker 
for predicting high-risk mastopathies and invasive 
breast cancers. 
4. ANTIHORMONES AND MODE OF 
ACTION 
Antisteroid hormones compete for hormone 
binding at the receptor level to prevent a hormonal 
response. Elucidation of the mechanisms by which 
antiestrogens inhibit proliferation and specific pro- 
tein synthesis in target cells was discussed by 
Benita Katzenellenbogen (Urbana). Whereas 
estrogen increases the rate of PR synthesis without 
influencing receptor degradation, progestin treat- 
ment in breast cancer cells causes both decrease in 
the synthesis and increase in the degradation of 
PR. Antiestrogens and antiprogestin RU 486 ap- 
pear to favor maintenance of the ER and PR in 
larger aggregate forms, which afford less effective 
interaction with chromatin binding sites. This sug- 
gestion is consistent with recent findings of 
Moudgil and Hurd that the ability of calf uterine 
PR to undergo 8 S to 4 S transformation in vitro 
is impaired when the receptor is occupied by RU 
486. Etienne Baulieu (Paris) proposed that a 
nonhormone-binding peptide, heat-shock protein 
of M, 90000 (hsp 90), is involved in the oligomeric 
structure of steroid receptors. The latter caps the 
DNA-binding site of the receptor to prevent it 
from binding to hormone-regulatory elements 
(HREs) to increase the transcription of regulatory 
genes. A hormone agonist may induce the dissocia- 
tion of the receptor oligomer to unmask the func- 
tional DNA-binding domain; RU 486-bound 
receptor, however, is stabilized in its 8 S form 
unable to dissociate from hsp 90 to elicit a hor- 
monal response. Thomas Ruh (St Louis) provided 
data to reveal that ER bound by antiestrogen, 
H 1285, interacts with antiestrogen specific sites 
but binds poorly to some chromatin sites which 
preferentially bind ER complexes. Ruh suggested 
that distinct nonhistone chromosomal proteins 
may play a role in biological actions induced by 
estrogens and antiestrogens. 
5. HORMONES AND BEHAVIOR 
Gonadal steroids are secreted in response to 
signals emanating from the brain and are known to 
influence animal behavior. Bruce McEwen (New 
York) studied the mechanism by which steroids 
regulate lardosis (mating) behavior of female rats 
in response to estradiol and progesterone. Induc- 
tion of lardosis involves hormonal activation of 
the genome of a small group of neurons in the ven- 
tromedial hypothalamus (VMN). Exposure of the 
VMN to testosterone early in life renders the 
animal defeminized. McEwen demonstrated that 
since the VMN contains the same density of ER in 
male and female rats, factors other than receptor 
must contribute to sex differences. 
6. ONCOGENES AND STEROID RECEPTORS 
Normal cellular genes have the ability to induce 
neoplastic growth. These ‘oncogenes’ or ‘proto- 
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oncogenes’ were the theme of the presentation of 
Inder Verma (San Diego), who discussed the 
transcriptional and post-transcriptional regulation 
of proto-oncogene fos. Proto-oncogene fos is an 
inducible gene whose expression is influenced by 
growht factors and stress. The resultant fos protein 
is susceptible to modification post-transcriptional- 
ly mainly by phosphorylation. Another proto- 
oncogene, rasH, is involved in tumorigenesis 
of human breast cancer cells. Edward Gelman 
(Bethesda) investigated the influences of rasH ex- 
pression levels and activating mutations on tumori- 
genesis by these cells by transfecting into MCF-7 
cells isogenic constructs of the rasH gene with only 
single point mutations. Of the rasH gene mutants, 
only the V-rasH homologue conferred an increased 
incidence of tumor’ formation on the MCF-7 cells 
in the absence of estrogen, but estrogen was re- 
quired for maximal tumor growth. 
7. CLONING AND EXPRESSION OF 
STEROID RECEPTOR GENES 
It is widely acknowledged that steroids influence 
cellular function by regulating gene expression. 
The steroid receptor structure-function analysis 
has been facilitated by recent success in the cloning 
and expression of complementary DNAs (cDNAs) 
corresponding to the estrogen, glucocorticoid and 
progestin receptors. In an attempt to define func- 
tional domains of the human androgen receptor 
(AR) involved in gene regulation, Govindan 
(Quebec) isolated cDNA clones encoding AR from 
human testis A-gt-11 cDNA library. The cDNA 
clones were inserted into a bacterial expression vec- 
tor. The protein product of the clones bound 
[3H]DHT with high affinity and specificity. To 
elucidate mechanisms by which steroids control 
target tissue gene expression, Olli Janne (New 
York) reported AR-mediated androgenic regula- 
tion of the ornithine decarboxylase (ODC) genes. 
Androgen treatment of female mice increased 
ODC mRNA accumulation and ODC protein con- 
centration. Although antiandrogens exhibited a 
dose-dependent accumulation of androgen recep- 
tors in the renal nuclei, receptor-antagonist com- 
plexes failed to influence gene expression. 
Hinrich Gronemeyer (Strasbourg) demonstrated 
that amino acid sequences of ER from human and 
chicken reveal three highly conserved regions: A 
(AA l-38), C (AA 180-263) and E (AA 302-553). 
All steroid receptors and V-erb A/thyroid receptor 
contain sequences homologous to regions C and E. 
Region E represents the steroid-binding domain, 
and region C, which contains the putative DNA- 
binding ‘fingers’, is required for tight nuclear 
binding. Both regions C and E are required for ef- 
ficient activation of the HREs of various genes 
studied. 
Edwin -Milgrom (Paris) presented data on the 
cloning of rabbit and human PR genes. Using elec- 
tron microscopy to observe PR binding to 
regulatory regions of uteroglobin and mouse mam- 
mary tumor virus genes, Milgrom and colleagues 
demonstrated the binding of PR oligomers at two 
DNA sites. The interaction results in DNA-loops 
when the HREs were at a distance from one 
another. The data suggested high-affinity interac- 
tion between steroid receptors and discrete regions 
of DNA. An understanding of regulatory se- 
quences in the rat prolactin and growth hormone 
genes has permitted Michael Rosenfeld (La Jolla) 
and co-workers to define cooperative interactions 
in the functional effects of the transcriptional ac- 
tivators, estrogen and T3. He discussed the rela- 
tionship between the above homeostatic regulators 
and tissue-specific transcriptional factors, noting 
that the regulatory proteins and the transcription 
factors differ in their DNA-binding properties. 
The conference presentations have provided fur- 
ther impetus to examine and scrutinize receptor 
structure closely, the genes responsible for their 
synthesis and cellular factors which potentially 
modulate both gene expression and receptor activi- 
ty. Future work in the molecular biology of steroid 
receptors should aid in understanding the precise 
structure-functional relationship, and allow in 
vitro mutagenesis to locate the inter-receptor 
binding regions and correlate them with a function 
or biological activity. As these mysteries unfold, 
society will benefit distinctly from the clinical ap- 
plications of this information. 
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